![](/en/images/pipeline_banner.jpg)
R&D Pipeline
R&D Pipeline
Guided by innovation and internationalization, Fosun Pharma increases its investment in R&D and the introduction of scientific research personnel, enriches its innovative product pipelines, improves its R&D and clinical trial capacities for new drugs, and speeds up the R&D and transformation of innovative technologies and products through diverse and multi-level cooperation models, such as independent R&D, co-development, in-licensing, and in-depth incubation.
![](/en/images/pipeline_img.jpg)
Main pipelines
Data as of the end of 2022, Fosun Pharma had more than 260 pipelines under development, including innovative drugs, biosimilars, generic drugs and those for consistency evaluation.
-
- 6
- self-developed innovator drugs (indications)
-
- 4
- license-in innovator drugs (indications)
-
- 27
- generic drugs (indications) of Fosun Pharma were approved for marketing in Chinese mainland/Hong Kong, China/United States
-
- 7
- innovator drugs (indications)
-
- 30
- generic drugs (indications) were applied for marketing in the Chinese mainland (NDA)
-
- 22
- innovator drugs (indications) were approved for clinical trials (IND) in the Chinese mainland.